卡格列净在2型糖尿病合并CKD患者中肾脏相关不良事件的影响:CREDENCE随机试验分析
CREDENCE试验事后分析纳入4401例T2DM合并CKD且UACR>300-5000 mg/g的患者,随机接受卡格列净100mg/d或安慰剂。卡格列净降低总体肾脏相关不良事件发生率(60.2 vs 84.0/1000患者年,HR 0.71,95%CI 0.61-0.82,P<0.001),严重肾脏相关不良事件和AKI风险数值上较低但未达显著,AKI后30天内肾功能完全恢复更常见。
要点
- 卡格列净降低总体肾脏相关不良事件发生率(HR 0.71)。
- 严重肾脏相关不良事件(HR 0.72)和AKI(HR 0.85)风险数值降低但未显著。
- AKI后30天内肾功能完全恢复比例卡格列净组更高(53.1% vs 35.4%)。
核心结论
- 与安慰剂相比,卡格列净降低T2DM合并CKD患者严重和非严重肾脏相关不良事件的发生率,支持其肾脏安全性。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心国际试验(CREDENCE)的事后分析,纳入4401例T2DM合并CKD且UACR>300-5000 mg/g的患者。
主要发现
- 总体肾脏相关不良事件发生率卡格列净组60.2 vs 安慰剂组84.0/1000患者年,HR 0.71(95%CI 0.61-0.82),P<0.001。
- 严重肾脏相关不良事件HR 0.72(95%CI 0.51-1.00),P=0.05;AKI HR 0.85(95%CI 0.64-1.13),P=0.3。
- 三个eGFR分层(30-<45、45-<60、60-<90 mL/min/1.73m2)肾脏相关不良事件HR分别为0.73、0.60、0.81,交互P=0.3;AKI交互P=0.9。
- AKI事件后30天内肾功能完全恢复卡格列净组53.1% vs 安慰剂组35.4%,OR 2.2(95%CI 1.0-4.7),P=0.04。
临床怎么用
- 对于T2DM合并CKD且UACR>300-5000 mg/g的患者,卡格列净可减少肾脏相关不良事件,支持其肾脏安全性。
- 卡格列净治疗期间发生AKI后肾功能完全恢复的可能性更高。
局限性
- 肾脏相关不良事件包括AKI由研究者报告,未经中心裁定。
- 未测量AKI和肾小管结构损伤的生物标志物。
- 并非所有参与者均有AKI事件后的肌酐数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial. This analysis of CREDENCE trial data examines the effect of canagliflozin on the incidence of kidney-related adverse events (AEs). STUDY DESIGN: A randomized, double-blind, placebo-controlled, multicenter international trial. SETTING & PARTICIPANTS: 4,401 trial participants with T2DM, CKD, and urinary albumin-creatinine ratio >300-5,000 mg/g. INTERVENTIONS: Participants were randomly assigned to receive canagliflozin 100 mg/d or placebo. OUTCOMES: Rates of kidney-related AEs were analyzed using an on-treatment approach, overall and by screening estimated glomerular filtration rate (eGFR) strata (30-<45, 45-<60, and 60-<90 mL/min/1.73 m2). RESULTS: Canagliflozin was associated with a reduction in the overall incidence rate of kidney-related AEs (60.2 vs 84.0 per 1,000 patient-years; hazard ratio [HR], 0.71 [95% CI, 0.61-0.82]; P < 0.001), with consistent results for serious kidney-related AEs (HR, 0.72 [95% CI, 0.51-1.00]; P = 0.05) and acute kidney injury (AKI; HR, 0.85 [95% CI, 0.64-1.13]; P = 0.3). The rates of kidney-related AEs were lower with canagliflozin relative to placebo across the 3 eGFR strata (HRs of 0.73, 0.60, and 0.81 for eGFR 30-<45, 45-<60, and 60-<90 mL/min/1.73 m2, respectively; P = 0.3 for interaction), with similar results for AKI (P = 0.9 for interaction). Full recovery of kidney function within 30 days after an AKI event occurred more frequently with canagliflozin versus placebo (53.1% vs 35.4%; odds ratio, 2.2 [95% CI, 1.0-4.7]; P = 0.04). LIMITATIONS: Kidney-related AEs including AKI were investigator-reported and collected without central adjudication. Biomarkers of AKI and structural tubular damage were not measured, and creatinine data after an AKI event were not available for all participants. CONCLUSIONS: Compared with placebo, canagliflozin was associated with a reduced incidence of serious and nonserious kidney-related AEs in patients with T2DM and CKD. These results highlight the safety of canagliflozin with regard to adverse kidney-related AEs. FUNDING: The CREDENCE trial and this analysis were funded by Janssen Research & Development, LLC, and were conducted as a collaboration between the funder, an academic steering committee, and an academic research organization, George Clinical. TRIAL REGISTRATION: The CREDENCE trial was registered at ClinicalTrials.gov with identifier number NCT02065791.
引用
- Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. Am J Kidney Dis. 2021. PMID: 34029680. doi:10.1053/j.ajkd.2021.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。